SSRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SSRM is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has supportive analyst upgrades and a favorable options setup, but the current price is already under pressure with a sharp daily drop, hedge fund selling is heavy, and there is no fresh news or financial quarter data to justify an immediate long-term purchase. If the investor is impatient and wants to act now, this is a hold rather than a buy.
Current price is 31.38, down 8.23% on the day and 7.07% pre-market, showing immediate weakness. Still, the broader technical structure is not fully bearish: SMA_5 is above SMA_20 and SMA_20 is above SMA_200, which is a bullish moving-average alignment. MACD histogram is positive at 0.245 but contracting, suggesting momentum is fading. RSI_6 at 40.723 is neutral-to-weak, not yet oversold enough to clearly signal a bounce. Key levels: pivot 32.38, support 29.271, resistance 35.49. Overall, trend is mixed with short-term weakness against a still-positive medium-term structure.
["Analysts have been steadily raising price targets and maintaining Buy/Outperform ratings.", "CIBC upgraded SSR Mining to Outperformer and lifted its target to 48, citing the Copler divestiture and balance sheet improvement.", "Canaccord, TD Securities, Scotiabank, UBS, National Bank, and BofA all showed improving sentiment in recent updates.", "Bullish options positioning with low put-call ratios suggests traders expect upside recovery.", "Technical moving averages remain bullish overall (SMA_5 > SMA_20 > SMA_200)."]
["The stock is down sharply today and pre-market, showing strong near-term selling pressure.", "Hedge funds are selling heavily, with selling up 763.19% over the last quarter.", "No news catalyst in the last week to support immediate upside.", "No recent congress trading data and no influential insider/politician buying signal.", "MACD momentum is positive but contracting, implying weakening trend strength."]
No latest quarter financial snapshot was available, so there is no confirmed quarter-by-quarter revenue or earnings update to assess. Based on the data provided, there is no recent financial performance catalyst to support a fresh long-term buy decision.
Analyst sentiment is clearly positive and improving. Recent actions include UBS raising its target to $44 and keeping Buy, Scotiabank raising to C$55 and keeping Outperform, CIBC upgrading to Outperformer with a $48 target, Canaccord lifting to C$58, TD Securities raising to C$53, National Bank upgrading to Outperform, and BofA upgrading to Buy. The Wall Street pro view is bullish on the Copler divestiture and balance sheet improvement, while the main con is that market price weakness and hedge fund selling are not yet fully reflected in the analyst optimism.
